Is it possible to get a titer for H1N1?

  1. 0
    I got a pretty severe respiratory illness about a month ago, complete with fever, body aches, and productive cough. I felt like I was hit by a bus. Now I'm wondering if it was H1N1, and if so, could I get a titer to see if I have immunity.
  2. Get the Hottest Nursing Topics Straight to Your Inbox!

  3. 8 Comments so far...

  4. 0
    This is all the information I could find on N1H1 titers. Maybe indigo girl will know something more.

    http://content.nejm.org/cgi/content/full/NEJMoa0907413
  5. 0
    I doubt that you will get a titer due to labs already being overwhelmed with H1N1 tests.
  6. 0
    Quote from HonestRN
    I doubt that you will get a titer due to labs already being overwhelmed with H1N1 tests.
    That would be my guess also. There are just too many people getting sick right now.
  7. 0
    I completely agree indigo girl! The general populace as well as the laboratory virologists and microbiologists as more concerned with creating the titers in a more productive way or just treating the mass amount of patients being seen for " suspected" N1H1.
  8. 0
    If labs aren't testing, then how do they know that the illnesses they are seeing are actually swine flu?
  9. 0
    Thinking that all of these sick people must have something else besides swine flu?

    The labs are testing. They never stopped testing, but we are now in the 2d wave, and there are too many people presenting with ILI to test everyone. Treatment is now being based on clinical presentation. They might do a rapid flu test, but by now, everyone is aware that these tests are frquently negative when the case is actually positive. Clinicians are told to treat based on the case presentation, and Tamiflu is usually reserved for the sickest or those at risk for adverse outcome.

    This wave has not peaked. The deaths attributed to pneumonia and flu remain below epidemic thresholds thus far.

    http://www.cdc.gov/flu/weekly/

    Quote from www.cdc.gov

    2008-2009 Influenza Season Week 38 ending September 26, 2009
    All data are preliminary and may change as more reports are received.

    Synopsis:
    During week 38 (September 20-26, 2009), influenza activity remained elevated in the U.S

    2,126 (22.8%) specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive for influenza.

    99% of all subtyped influenza A viruses being reported to CDC were 2009 influenza A (H1N1) viruses.

    The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.

    Eleven influenza-associated pediatric deaths were reported and all eleven were associated with 2009 influenza A (H1N1) virus infection.

    The proportion of outpatient visits for influenza-like illness (ILI) was above the national baseline. Regions 2 through 10 reported ILI above region-specific baseline levels; only Region 1 was below its region-specific baseline.
    Twenty-seven states reported geographically widespread influenza activity, Guam and 18 states reported regional influenza activity, two states, the District of Columbia, and Puerto Rico reported local influenza activity, one state reported sporadic influenza activity, and the U.S. Virgin Islands and two states did not report.

    The 2009-10 influenza season officially begins October 4, 2009.
  10. 0
    http://www.cdc.gov/flu/weekly/fluactivity.htm

    So how do we know what is going on if they don't test every case?

    Quote from www.cdc.gov
    Five Categories of Influenza Surveillance

    1. Viral Surveillance — About 80 U.S. World Health Organization (WHO) Collaborating Laboratories and 70 National Respiratory and Enteric Virus Surveillance System (NREVSS), located throughout the United States participate in virologic surveillance for influenza. All state public health laboratories participate as WHO collaborating laboratories along with some county public health laboratories and some large tertiary care or academic medical centers. Most NREVSS laboratories participating in influenza surveillance are hospital laboratories. The WHO and NREVSS collaborating laboratories report the total number of respiratory specimens tested and the number positive for influenza types A and B each week to CDC. Most of the U.S. WHO collaborating laboratories also report the influenza A subtype (H1 or H3) of the viruses they have isolated and the ages of the persons from whom the specimens were collected. The majority of NREVSS laboratories do not report the influenza A subtype. Reports from both sources are combined and the weekly total number of positive influenza tests, by virus type/subtype, and the percent of specimens testing positive for influenza are presented in the weekly influenza update, FluView. Some of the influenza viruses collected by U.S. WHO collaborating laboratories are sent to CDC for further characterization, including gene sequencing, antiviral resistance testing and antigenic determination. This information is presented in the antigenic characterization and antiviral resistance sections of the FluView report.

    Surveillance for Novel Influenza A Viruses- In 2007, human infection with a novel influenza A virus became a nationally notifiable condition. Novel influenza A virus infections include all human infections with influenza A viruses that are different from currently circulating human influenza H1 and H3 viruses. These viruses include those that are subtyped as nonhuman in origin and those that are unsubtypable with standard methods and reagents. Rapid reporting of human infections with novel influenza A viruses will facilitate prompt detection and characterization of influenza A viruses and accelerate the implementation of effective public health responses.

    2. Outpatient Illness Surveillance — Information on patient visits to health care providers for influenza-like illness is collected through the US Outpatient Influenza-like Illness Surveillance Network (ILINet).

    The Outpatient Influenza-like Illness Surveillance Network (ILINet) consists of about 2,400 healthcare providers in 50 states reporting approximately 16 million patient visits each year. Each week, approximately 1,300 outpatient care sites around the country report data to CDC on the total number of patients seen and the number of those patients with influenza-like illness (ILI) by age group. For this system, ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and a cough and/or a sore throat in the absence of a KNOWN cause other than influenza. Sites with electronic records use an equivalent definition as determined by the state public health authorities. The percentage of patient visits to healthcare providers for ILI reported each week is weighted on the basis of state population. This percentage is compared each week with the national baseline of 2.4%. The baseline is the mean percentage of patient visits for ILI during non-influenza weeks for the previous three seasons plus two standard deviations. Due to wide variability in regional level data, it is not appropriate to apply the national baseline to regional data, therefore, region specific baselines are calculated.

    Regional baselines for the 2008-09 influenza season are:

    New England — 1.5%
    Connecticut, Maine, Massachusetts, New Hampshire, Vermont, Rhode Island

    Mid-Atlantic — 2.9%
    New Jersey, New York City, Pennsylvania, Upstate New York

    East North Central — 1.9%
    Illinois, Indiana, Michigan, Ohio, Wisconsin

    West North Central — 1.7%
    Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota

    South Atlantic — 2.2%
    Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, Washington, D.C., West Virginia

    East South Central — 2.5%
    Alabama, Kentucky, Mississippi, Tennessee

    West South Central — 4.8%
    Arkansas, Louisiana, Oklahoma, Texas

    Mountain — 1.5%
    Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming

    Pacific — 3.0%
    Alaska, California, Hawaii, Oregon, Washington

    3. Mortality Surveillance — Rapid tracking of influenza-associated deaths is done through two systems:

    122 Cities Mortality Reporting System — Each week, the vital statistics offices of 122 cities report the total number of death certificates received and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group. The percentage of all deaths due to pneumonia and influenza (P&I) are compared with a seasonal baseline and epidemic threshold value calculated for each week. The seasonal baseline of P&I deaths is calculated using a periodic regression model that incorporates a robust regression procedure applied to data from the previous five years. An increase of 1.645 standard deviations above the seasonal baseline of P&I deaths is considered the “epidemic threshold,” i.e., the point at which the observed proportion of deaths attributed to pneumonia or influenza was significantly higher than would be expected at that time of the year in the absence of substantial influenza-related mortality.

    Surveillance for Influenza-associated Pediatric Mortality — Influenza-associated deaths in children (persons less than 18 years) was added as nationally notifiable condition in 2004. Laboratory-confirmed influenza-associated deaths in children are reported through the Nationally Notifiable Disease Surveillance System.

    4. Hospitalization Surveillance — Two systems monitor hospitalizations with laboratory confirmed influenza infections.

    Emerging Infections Program (EIP) — The EIP Influenza Project conducts surveillance for laboratory-confirmed influenza related hospitalizations in children (persons less than 18 years) and adults in 60 counties covering 12 metropolitan areas of 10 states (San Francisco CA, Denver CO, New Haven CT, Atlanta GA, Baltimore MD, Minneapolis/St. Paul MN, Albuquerque NM, Las Cruces, NM, Albany NY, Rochester NY, Portland OR, and Nashville TN). Cases are identified by reviewing hospital laboratory and admission databases and infection control logs for children and adults with a documented positive influenza test (viral culture, direct/indirect fluorescent antibody assay (DFA/IFA), reverse transcription-polymerase chain reaction (RT-PCR), or a commercial rapid antigen test) conducted as a part of routine patient care. EIP estimated hospitalization rates are reported every two weeks during the influenza season.
    New Vaccine Surveillance Network (NVSN) — The New Vaccine Surveillance Network (NVSN) provides population-based estimates of laboratory-confirmed influenza hospitalization rates for children less than 5 years old residing in three counties: Hamilton County OH, Davidson County TN, and Monroe County NY. Children admitted to NVSN hospitals with fever or respiratory symptoms are prospectively enrolled and respiratory samples are collected and tested by RT-PCR and viral culture. NVSN estimated rates are reported every two weeks during the influenza season.

    5. Summary of the Geographic Spread of Influenza — State health departments report the estimated level of spread of influenza activity in their states each week through the State and Territorial Epidemiologists Reports. States report influenza activity as no activity, sporadic, local, regional, or widespread. These levels are defined as follows:

    No Activity: No laboratory-confirmed cases of influenza and no reported increase in the number of cases of ILI.
    Sporadic: Small numbers of laboratory-confirmed influenza cases or a single laboratory-confirmed influenza outbreak has been reported, but there is no increase in cases of ILI.
    Local: Outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in a single region of the state.
    Regional:Outbreaks of influenza or increases in ILI and recent laboratory confirmed influenza in at least two but less than half the regions of the state with recent laboratory evidence of influenza in those regions.
    Widespread:Outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in at least half the regions of the state with recent laboratory evidence of influenza in the state.

    Together, the five categories of influenza surveillance are designed to provide a national picture of influenza activity. Pneumonia and influenza mortality is reported on a national level only. Outpatient illness and laboratory data are reported on a national level and by influenza surveillance region.

    The state and territorial epidemiologists' reports of influenza activity are the only state-level information reported. Both the EIP and NVSN data provide population-based, laboratory-confirmed estimates of influenza-related hospitalizations but are reported from limited geographic areas.
  11. 0
    This sounds similar to what they do with AIDs cases in Africa. They don't have the resources to test everyone so that have to go by the symptoms.


Top